ValuEngine upgraded shares of Five Prime Therapeutics (NASDAQ:FPRX) from a sell rating to a hold rating in a research note published on Thursday, ValuEngine reports.
Other analysts also recently issued reports about the stock. Wells Fargo & Co downgraded shares of Five Prime Therapeutics from an outperform rating to a market perform rating and cut their price objective for the company from $35.00 to $10.00 in a research report on Monday, June 3rd. Roth Capital started coverage on shares of Five Prime Therapeutics in a research report on Wednesday, May 29th. They set a neutral rating and a $10.00 price objective on the stock. BidaskClub downgraded shares of Five Prime Therapeutics from a hold rating to a sell rating in a research report on Tuesday, May 14th. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 31st. Finally, Guggenheim started coverage on shares of Five Prime Therapeutics in a research report on Friday, April 12th. They set a buy rating and a $24.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of Hold and an average price target of $20.00.
FPRX stock traded down $0.01 during trading on Thursday, hitting $5.09. 15,055 shares of the stock traded hands, compared to its average volume of 421,212. Five Prime Therapeutics has a 1 year low of $4.90 and a 1 year high of $16.00. The stock has a 50 day simple moving average of $5.80. The stock has a market capitalization of $183.93 million, a PE ratio of -1.22 and a beta of 2.59. The company has a current ratio of 10.41, a quick ratio of 10.41 and a debt-to-equity ratio of 0.21.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.05. Five Prime Therapeutics had a negative net margin of 683.89% and a negative return on equity of 54.87%. The company had revenue of $5.35 million for the quarter, compared to the consensus estimate of $5.71 million. As a group, equities research analysts anticipate that Five Prime Therapeutics will post -3.75 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its position in shares of Five Prime Therapeutics by 4.4% during the 4th quarter. BlackRock Inc. now owns 3,039,915 shares of the biotechnology company’s stock valued at $28,269,000 after buying an additional 127,777 shares in the last quarter. Northern Trust Corp raised its position in Five Prime Therapeutics by 0.5% in the 4th quarter. Northern Trust Corp now owns 425,775 shares of the biotechnology company’s stock worth $3,959,000 after purchasing an additional 2,278 shares during the period. Dimensional Fund Advisors LP raised its position in Five Prime Therapeutics by 5.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,484,178 shares of the biotechnology company’s stock worth $13,803,000 after purchasing an additional 71,001 shares during the period. Geode Capital Management LLC raised its position in Five Prime Therapeutics by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 409,701 shares of the biotechnology company’s stock worth $3,810,000 after purchasing an additional 38,601 shares during the period. Finally, D. E. Shaw & Co. Inc. purchased a new position in Five Prime Therapeutics in the 4th quarter worth $140,000. Institutional investors and hedge funds own 86.93% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
See Also: Cost of Goods Sold (COGS)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.